Methyl-CpG Binding Protein 2 in Alzheimer Dementia
Baeksun Kim1,2, Yunjung Choi3,4, Hye-Sun Kim3,4
1Convergence Research Center for Diagnosis, Treatment and Care System of Dementia (DTC), Korea Institute of Science and Technology (KIST), Seoul, Korea.
International Neurourology Journal
|December 5, 2019
Summary
Methyl-CpG Binding Protein 2 (MeCP2) plays a key role in Alzheimer disease. Imbalances in MeCP2 function can accelerate Alzheimer disease pathogenesis, suggesting it as a potential therapeutic target.
Area of Science:
- Neuroscience
- Epigenetics
- Molecular Biology
Background:
- Alzheimer disease (AD) pathogenesis involves complex genetic and molecular interactions.
- Methyl-CpG Binding Protein 2 (MeCP2) is an epigenetic regulator crucial in brain function.
- Emerging evidence highlights MeCP2's significant role in Alzheimer disease.
Purpose of the Study:
- To comprehensively review the pathophysiological roles of MeCP2 in Alzheimer disease.
- To elucidate how MeCP2 alterations impact AD through risk genes, proteinopathies, and neurodegeneration.
- To explore MeCP2's influence on glial senescence and neuroinflammation in AD.
Main Methods:
- Literature review and synthesis of existing research on MeCP2 and Alzheimer disease.
- Analysis of MeCP2's impact on AD-associated genetic risk factors.
- Examination of MeCP2's role in neuronal cell death pathways (excitotoxicity, apoptosis).
- Investigation of MeCP2's effect on glial senescence and the senescence-associated secretory phenotype (SASP).
Main Results:
- Upregulated MeCP2 represses AD risk genes (MEF2C, ADAM10, PM20D1), exacerbating AD.
- Altered MeCP2 contributes to increased tau pathology and neurodegeneration via neuronal cell death.
- Reduced MeCP2 impairs glial senescence, leading to detrimental neuroinflammation via SASP.
Conclusions:
- MeCP2 dysregulation significantly influences Alzheimer disease progression.
- MeCP2's multifaceted roles in gene regulation, neurodegeneration, and neuroinflammation position it as a critical factor in AD.
- Modulating MeCP2 function presents a promising therapeutic strategy for Alzheimer disease treatment and prevention.
